FDA Approved: NIKTIMVO — Original Application (Incyte Corporation)

View source ↗

Summary

FDA approved NIKTIMVO (axatilimab-csfr) from Incyte in an original Biologics License Application for the treatment of chronic graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• NIKTIMVO (AXATILAB-CSFR)

Snippet

ORIG AP for NIKTIMVO (AXATILIMAB-CSFR)